Goldman Sachs
FTH

Goldman Sachs’s Faeth Therapeutics FTH Stock Holding History

Goldman Sachs’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-61,568
Closed -$1.94M – 6961
2026
Q1 		$1.94M Buy
+61,568
New +$1.23M ﹤0.01% 4568
2022
Q4 		– Sell
-522
Closed -$16K – 6243
2022
Q3 		$16K Sell
522
-31
-6% -$1.22K ﹤0.01% 5969
2022
Q2 		$25K Sell
553
-81
-13% -$3.04K ﹤0.01% 6142
2022
Q1 		$29K Buy
634
+79
+14% +$6.29K ﹤0.01% 6358
2021
Q4 		$64K Buy
+555
New +$82.9K ﹤0.01% 6222

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Goldman Sachs's FTH Position: Q2 2026 in Review

Goldman Sachs sold out of Faeth Therapeutics (FTH) in Q2 2026, closing a stake of 61,568 shares — an estimated $1.94M sold.

Goldman Sachs first reported a position in FTH in Q4 2021 and held it in 5 quarters. The position peaked at $1.94M in Q1 2026. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Goldman Sachs reported no remaining Faeth Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 61,568 Faeth Therapeutics shares in Q2 2026, an estimated $1.94M.
  • Goldman Sachs first reported a position in Faeth Therapeutics in Q4 2021 and held it in 5 quarters.
  • Goldman Sachs's Faeth Therapeutics position peaked at $1.94M in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.